PMID- 25214752
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 2224-6614 (Electronic)
IS  - 1021-9498 (Print)
VI  - 21
IP  - 4
DP  - 2013 Dec
TI  - HIV treatment as prevention: the key to an AIDS-free generation.
PG  - S95-S101
AB  - The presence of elevated HIV viral load within blood and genital secretions is a 
      critical driver of transmission events. Long-term suppression of viral load to 
      undetectable levels through the use of antiretroviral therapy is now standard 
      practice for clinical management of HIV. Antiretroviral therapy therefore can 
      play a key role as a means to curb HIV transmission. Results of a randomized 
      clinical trial, in conjunction with several observational studies, have now 
      confirmed that antiretroviral therapy markedly decreases HIV transmission risk. 
      Mathematical models and population-based ecologic studies suggest that further 
      expansion of antiretroviral coverage within current guidelines can play a major 
      role in controlling the spread of HIV. Expansion of so-called "Treatment as 
      Prevention" initiatives relies upon maximal uptake of the HIV continuum-of-care 
      cascade to allow for successful identification of those not yet known to be 
      HIV-infected, engagement of patients in appropriate care, and subsequently 
      achieving sustained virologic suppression in patients with the use of 
      antiretroviral therapy. Since 2010, the Joint United Nations AIDS (UNAIDS) 
      program has called for the inclusion of antiretroviral treatment as a key pillar 
      in the global strategy to control the spread of HIV infection. This has now been 
      invigorated by the release of the World Health Organization's 2013 Consolidated 
      Antiretroviral Therapy Guidelines, recommending treatment to be offered to all 
      HIV-infected individuals with CD4 cell counts below 500/mm(3), and, regardless of 
      CD4 cell count, to serodiscordant couples, TB and HBV co-infected individuals, 
      pregnant women, and children below the age of 5 years.
FAU - Hull, Mark W
AU  - Hull MW
AD  - Division of AIDS, Department of Medicine, University of British Columbia, 
      Vancouver, Canada.
FAU - Montaner, Julio S G
AU  - Montaner JS
AD  - Division of AIDS, Department of Medicine, University of British Columbia, 
      Vancouver, Canada.
LA  - eng
GR  - DP1 DA026182/DA/NIDA NIH HHS/United States
GR  - P30 DA016383/DA/NIDA NIH HHS/United States
GR  - R01 DA031043/DA/NIDA NIH HHS/United States
GR  - R13 DA035084/DA/NIDA NIH HHS/United States
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - J Food Drug Anal
JT  - Journal of food and drug analysis
JID - 101630927
PMC - PMC4158850
MID - NIHMS599645
OTO - NOTNLM
OT  - HIV care cascade
OT  - Seek and Treat
OT  - Treatment as Prevention
OT  - linkage to care
COIS- Conflict of interest statement: Dr. Mark Hull receives support from the U.S. 
      National Institute on Drug Abuse (grant number R01DA031043-01). He has served on 
      speakers bureau or advisory boards of Merck, Janssen, Vertex, 
      Bristol-Myers-Squibb, ViiV, Pfizer. Dr. Julio Montaner is supported by the 
      British Columbia Ministry of Health; through an Avant-Garde Award (No. 
      1DP1DA026182) from the National Institute on Drug Abuse (NIDA), at the U.S. 
      National Institutes of Health (NIH); and through a Knowledge Translation Award 
      from the Canadian Institutes of Health Research (CIHR). He has also received 
      financial support from the International AIDS Society, United Nations AIDS 
      Program, World Health Organization, National Institutes of Health Research-Office 
      of AIDS Research, National Institute of Allergy & Infectious Diseases, The United 
      States President's Emergency Plan for AIDS Relief (PEPfAR), Bill & Melinda Gates 
      Foundation, French National Agency for Research on AIDS & Viral Hepatitis (ANRS), 
      the Public Health Agency of Canada, the University of British Columbia, Simon 
      Fraser University, Providence Health Care, and Vancouver Coastal Health 
      Authority. He has received grants from Abbott, Biolytical, Boehringer-Ingelheim, 
      Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare.
EDAT- 2014/09/13 06:00
MHDA- 2014/09/13 06:01
PMCR- 2014/09/09
CRDT- 2014/09/13 06:00
PHST- 2014/09/13 06:00 [entrez]
PHST- 2014/09/13 06:00 [pubmed]
PHST- 2014/09/13 06:01 [medline]
PHST- 2014/09/09 00:00 [pmc-release]
AID - S1021-9498(13)00107-5 [pii]
AID - 10.1016/j.jfda.2013.09.043 [doi]
PST - ppublish
SO  - J Food Drug Anal. 2013 Dec;21(4):S95-S101. doi: 10.1016/j.jfda.2013.09.043.